NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration
NeuroMetrix, Inc. (NURO)
Last neurometrix, inc. earnings: 4/20 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.neurometrix.com/investor-relations
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare. Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development of Quell® technology beginning in 2019, subject to agreement on an annual program of product initiatives. The Company reported that agreement has been reached on the 2019 development program and it will commence in January 2019. The parties modified the terms of the collaboration to reallocate the up to $13.8 million remaining to be paid by GSK upon the achievement of certain development and commercial milestones. These modifications accelerated a portion of the remaining milestones timing into the next twelve months while reducing the aggregate milestone amount payable by an interest charge. NeuroMetrix received a $2 million milestone payment from GSK in connection with such modifications.
Show less
Read more
Impact Snapshot
Event Time:
NURO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NURO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NURO alerts
High impacting NeuroMetrix, Inc. news events
Weekly update
A roundup of the hottest topics
NURO
News
- NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy [Yahoo! Finance]Yahoo! Finance
- NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyGlobeNewswire
- Point Of Care Diagnostics Market By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By End-use (Clinics, Home, Hospitals), By Region, And Segment Forecasts, 2024 - 2030 [Yahoo! Finance]Yahoo! Finance
- NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia [Yahoo! Finance]Yahoo! Finance
- NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaGlobeNewswire
NURO
Sec Filings
- 3/27/24 - Form DEF
- 3/6/24 - Form 4
- 3/6/24 - Form 4
- NURO's page on the SEC website